The K252a derivatives, inhibitors for the PAK/MLK kinase family selectively block the growth of RAS transformants.

The K252a derivatives, inhibitors for the PAK/MLK kinase family selectively block the growth of RAS transformants. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

The K252a derivatives, inhibitors for the PAK/MLK kinase family selectively block the growth of RAS transformants. Abstract Text:

BACKGROUND: Oncogenic RAS mutants such as v-Ha-RAS activate members of Rac/CDC42-dependent kinases (PAKs) and appear to contribute to the development of more than 30% of all human cancers. PAK1 activation is essential for oncogenic RAS transformation, and several chemical compounds that inhibit Tyr kinases essential for the RAS-induced activation of PAK1 strongly suppress RAS transformation either in cell culture or in vivo (nude mice). Although we have developed a cell-permeable PAK-specific peptide inhibitor called WR-PA18, so far no chemical (metabolically stable) compound has been developed that directly inhibits PAK1 in a highly selective manner. Thus, we have explored such a PAK1 inhibitor(s) among synthetic derivatives of an adenosine triphosphate antagonist. RESULTS: From the naturally occurring adenosine triphosphate antagonist K252a, we have developed two bulky derivatives, called CEP-1347 and KT D606 (a K252a dimer), which selectively inhibit PAKs or mixed-lineage kinases both in vitro and in cell culture and convert v-Ha-RAS-transformed NIH 3T3 cells to flat fibroblasts similar to the parental normal cells. Furthermore, these two K252a analogues suppress the proliferation of v-Ha-RAS transformants, but not the normal cells. CONCLUSION: These bulky adenosine triphosphate antagonists derived from K252a or related indolocarbazole compounds such as staurosporine would be potentially useful for the treatment of RAS/ PAK1-induced cancers, once their anti-PAK1 activity is significantly potentiated by a few additional chemical modifications at the sugar ring suggested in this paper.

The K252a derivatives, inhibitors for the PAK/MLK kinase family selectively block the growth of RAS transformants. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE: 2002 Jul-Aug

The K252a derivatives, inhibitors for the PAK/MLK kinase family selectively block the growth of RAS transformants. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Cancer journal (Sudbury, Mass.)

VOLUME: 8

Page Numbers: 328-36

Journal Abbreviation:

ISSN: 1528-9117

DAY: 28

MONTH: 06

YEAR: 2008

The K252a derivatives, inhibitors for the PAK/MLK kinase family selectively block the growth of RAS transformants. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100931981

The K252a derivatives, inhibitors for the PAK/MLK kinase family selectively block the growth of RAS transformants. Keywords Mesh Terms:

KEYWORDS: Staurosporine

MESH TERMS: chemistry

Chemical & Substance for Abstract: The K252a derivatives, inhibitors for the PAK/MLK kinase family selectively block the growth of RAS transformants. Information

Substance Name: mitogen-activated protein kinase kinase

Registry Number: EC 2.7.11.25

Grant and Affiliation Information for The K252a derivatives, inhibitors for the PAK/MLK kinase family selectively block the growth of RAS transformants.

AFFILIATION: Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Parkville, Australia.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Cancer J

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

The K252a derivatives, inhibitors for the PAK/MLK kinase family selectively block the growth of RAS transformants Related Publications

• An anti-Ras cancer potential of PP1, an inhibitor specific for Src family kinases: in vitro and in vivo studies.
• Analysis of the conformational change of myosin during ATP hydrolysis using fluorescence resonance energy transfer.
• Atypical depression as a premonitory symptom of migraine managed by an oral contraceptive.
• Chirped nonlinear pulse propagation in a dispersion-compensated system.
• Conformational change of the loop L5 in rice kinesin motor domain induced by nucleotide binding.
• Depression associated with chronic pain: incidence, characteristics, and long-term outcome.
• Effect of abdominal surgery on glucose tolerance, plasma levels of insulin and glycogenic amino acids.
• Formation and characterization of kinesin.ADP.fluorometal complexes.
• Incorporation of an azobenzene derivative into the energy transducing site of skeletal muscle myosin results in photo-induced conformational changes.
• Intermolecular cross-linking of a novel rice Kinesin k16 motor domain with a photoreactive ATP derivative.
• Optimal design of dispersion management for a soliton wavelength-division-multiplexed system.
• PAK is essential for RAS-induced upregulation of cyclin D1 during the G1 to S transition.
• Photocontrol of Kinesin ATPase activity using an azobenzene derivative.
• Preparation and characterization of a novel rice plant-specific kinesin.
• Signal therapy for RAS-induced cancers in combination of AG 879 and PP1, specific inhibitors for ErbB2 and Src family kinases, that block PAK activation.
• Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance.
• The K252a derivatives, inhibitors for the PAK/MLK kinase family selectively block the growth of RAS transformants.
• The Tyr-kinase inhibitor AG879, that blocks the ETK-PAK1 interaction, suppresses the RAS-induced PAK1 activation and malignant transformation.